Cristal Therapeutics and TBD Pharmatech enter exclusive supply agreement for CliCr® conjugation reagents
Key Highlights:
• Exclusive Partnership: TBD Pharmatech will be the sole supplier of CliCr® to Cristal Therapeutics.
• Strategic Supply Security: The agreement secures a robust and high-quality supply of CliCr® for Cristal’s and its clients pipelines
• Commitment to Innovation: Both companies reaffirm their commitment to advancing innovative solutions in pharmaceutical drug product development and beyond.
Maastricht, The Netherlands /Tartu, Estonia – 23 September 2025
Cristal Therapeutics, a biotech developing innovative conjugation technologies, today announced the signing of an exclusive supply agreement with TBD Pharmatech, a leading European manufacturer of active pharmaceutical ingredients (APIs). Under this agreement, TBD Pharmatech will serve as the exclusive supplier of CliCr® conjugation reagents.
This agreement fortifies Cristal Therapeutics’ supply chain – a vital element for the seamless integration of CliCr® into diverse advanced therapeutic and diagnostic products. Leveraging TBD Pharmatech’s established expertise in high-purity (GMP-) manufacturing and rigorous quality assurance, this partnership guarantees the reliable and scalable production of CliCr® to support Cristal Therapeutics’ current and future initiatives.
The CliCr® bioconjugation platform offers excellent solutions for precise, site-specific, and robust conjugation of biomolecules. The technology enables a wide range of cutting-edge applications that allow for novel therapeutics and diagnostics to benefit patient treatment.
Dr. Werner Cautreels, CEO of Cristal Therapeutics, commented: “We are delighted to continue our partnership with TBD Pharmatech, whose manufacturing excellence and reliability are vital as we advance to outlicense CliCr to various third parties. This agreement is a testament to the successful development and scale-up performed by TBD. It marks a significant step in ensuring the consistent supply of our proprietary CliCr® technology. This deal will support the growing interest in our CliCr® platform, which continues to demonstrate broad applicability and robust performance in drug development.”
Dr. Andrus Tasa, CEO of TBD Pharmatech, added: “We are proud to become the exclusive supplier of CliCr for Cristal Therapeutics. Our collaboration underscores our shared dedication to quality and innovation in pharmaceutical manufacturing. At TBD Pharmatech, we are committed to providing the highest standards of excellence, reliability, and regulatory compliance, ensuring that our partners can bring safe and effective medicines to patients worldwide.”
The financial terms of the agreement were not disclosed.
